RELX share price nudges up on buyback update as Feb 12 results near

RELX share price nudges up on buyback update as Feb 12 results near

London, Jan 9, 2026, 11:37 GMT — Regular session

RELX (REL.L) shares edged higher in London on Friday after the information and analytics group flagged another round of buybacks. The stock was up 2 pence, or 0.06%, at 3,150 pence as of 1108 GMT. (Share Prices)

RELX bought 303,180 shares on Thursday through UBS, paying between 3,082 and 3,158 pence, the company said. It has repurchased about 1.57 million shares since Jan. 2, and the stock will be held in treasury. (Investegate)

The purchases sit inside a £250 million non-discretionary programme that runs from Jan. 2 to Feb. 6. Under the setup, the broker trades independently inside preset limits — a standard way to keep buybacks moving during sensitive periods ahead of results. (Investegate)

RELX moved with the wider market as the FTSE 100 rose about 0.4%, lifted by miners after Glencore jumped on merger talks with Rio Tinto. Investors also waited for a U.S. jobs report due later on Friday, with Morningstar strategist Michael Field urging a “healthy dose of scepticism” on deal chatter. (Reuters)

RELX sells scientific, technical, medical and legal information and analytics and runs exhibitions. It trades in London under the ticker REL and has listings in Amsterdam and New York. (Investegate)

Other UK data and analytics names were firmer, with Experian up 0.9% by mid-morning. RELX’s move looked more like a grind than a chase. (Share Prices)

The stock opened at 3,146 pence and has traded between 3,136 and 3,175 pence so far, Hargreaves Lansdown data showed. RELX also sits well below its 52-week high of 4,205 pence, and HL puts the shares on a price-to-earnings ratio of about 26. (Hargreaves Lansdown)

But buybacks do not do much if guidance jars. The next update on growth and margins matters more than the daily repurchase tally.

RELX is due to report full-year results for the year to Dec. 31, 2025 on Feb. 12 — the next clear catalyst for the RELX share price. (Relx)

CEO of TS2 Space and founder of TS2.tech. Expert in satellites, telecommunications, and emerging technologies, covering trends in space, AI, and connectivity.

Stock Market Today

  • AstraZeneca Shares Appear Undervalued Despite Steady Gains and Robust Pipeline
    January 30, 2026, 10:19 PM EST. AstraZeneca's (LSE:AZN) shares closed at £136.00, showing modest short-term fluctuations but robust long-term returns of 22.5% over one year and 109.6% over five years. The pharmaceutical giant's stock is currently rated 3 out of 6 on valuation checks. Analysis using a Discounted Cash Flow (DCF) model, which estimates present value based on future cash flows, suggests AstraZeneca is undervalued by 44.6% compared to its intrinsic value of about £245.66 per share. This undervaluation points to potential investment opportunities as AstraZeneca continues to benefit from strong pipeline developments and strategic partnerships that influence its long-term outlook and risk profile.
China SXT Pharmaceuticals (SXTC) stock whipsaws after AI “clinics” plan, with Friday open in focus
Previous Story

China SXT Pharmaceuticals (SXTC) stock whipsaws after AI “clinics” plan, with Friday open in focus

UK stock market today: FTSE100 rises as Glencore jumps on Rio takeover talks
Next Story

UK stock market today: FTSE100 rises as Glencore jumps on Rio takeover talks

Go toTop